Getinge (OTCMKTS:GNGBY) Sets New 52-Week High – Time to Buy?

Getinge (OTCMKTS:GNGBY) shares reached a new 52-week high during mid-day trading on Wednesday. The company traded as high as $26.88 and last traded at $26.76, with a volume of 2,714 shares trading hands. The stock had previously closed at $26.21.

Analysts Set New Price Targets

Several brokerages have issued reports on GNGBY. Pareto Securities downgraded Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. UBS Group assumed coverage on shares of Getinge in a report on Wednesday, September 2nd. They issued a “hold” rating on the stock. Finally, Nordea Equity Research lowered shares of Getinge from a “buy” rating to a “hold” rating in a research report on Monday, August 31st. Four equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, Getinge currently has a consensus rating of “Hold”.

Getinge Stock Performance

The firm has a market cap of $7.27 billion, a price-to-earnings ratio of 25.42 and a beta of 0.95. The stock has a 50 day moving average of $25.11 and a 200 day moving average of $22.69. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY) last released its earnings results on Wednesday, October 21st. The company reported $0.32 EPS for the quarter. Getinge had a net margin of 7.81% and a return on equity of 11.12%. As a group, analysts anticipate that Getinge will post 1.38 EPS for the current fiscal year.

Getinge Company Profile

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.